ACXP News and Press, Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference Acurx Pharmaceuticals Announces Presentation of Result...

2026-05-12 12:45:30 ET Image source: The Motley Fool. Tuesday, May 12, 2026 at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-05-12 11:01:50 ET More on Acurx Pharmaceuticals Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript Acurx Pharmaceuticals GAAP EPS of -$0.62 Acurx Pharmaceuticals announc...

2026-05-12 11:00:54 ET Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call May 12, 2026 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript

2026-05-12 08:30:13 ET More on Acurx Pharmaceuticals Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript Acurx Pharmaceuticals announces up to $7.1M offering Most and least shorted healthcare stocks with up to $2B market cap in March Seeking A...

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , May 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a ne...

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026 PR Newswire DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activity ...

Staten Island, New York--(Newsfile Corp. - April 27, 2026) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it will be par...

Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , April 20, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage b...

Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PR Newswire $2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-ter...